
Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Drugs In Development, 2022, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.
Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 3, 10, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 9, 1 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Drugs In Development, 2022, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.
Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 3, 10, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 9, 1 and 1 molecules, respectively.
Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
87 Pages
- Introduction
- Global Markets Direct Report Coverage
- Bone Metastasis – Overview
- Bone Metastasis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bone Metastasis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bone Metastasis – Companies Involved in Therapeutics Development
- Ablynx NV
- Airsea (Taizhou) Pharmaceutical Ltd
- AlaMab Therapeutics Inc
- Aptacure Therapeutics Ltd
- Better Life Pharmaceuticals Inc
- Biocon Ltd
- BiologicsMD Inc
- BioNTech SE
- Crescendo Biologics Ltd
- CSPC Pharmaceutical Group Ltd
- Eden Biologics Inc
- Genor BioPharma Co Ltd
- Hetero Labs Ltd
- Hualan Biological Engineering Inc
- ITM Isotope Technologies Munich SE
- Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabwell Shanghai Bioscience Co Ltd
- MetCure Therapeutics LLC
- NeuClone Pty Ltd
- Orion Biotechnology Canada Ltd
- PEKKIP Oncology Alliance AG
- Qilu Pharmaceutical Co Ltd
- QSAM Therapeutics Inc
- Sandoz International GmbH
- Serene LLC
- Shanghai Henlius Biotech Inc
- Sonnet BioTherapeutics Holdings Inc
- Bone Metastasis – Drug Profiles
- ALMB-0168 – Drug Profile
- ALX-0141 – Drug Profile
- Apc-002 – Drug Profile
- BKM-1644 – Drug Profile
- BKM-1740 – Drug Profile
- BMD-3151 – Drug Profile
- BonTarg – Drug Profile
- CB-307 – Drug Profile
- Cyclosam – Drug Profile
- denosumab biobetter – Drug Profile
- denosumab biosimilar – Drug Profile
- Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer – Drug Profile
- Drugs to Inhibit RANK for Bone Metastasis – Drug Profile
- FUBIS – Drug Profile
- Fusion Protein to Antagonize PTH for Breast Cancer and Bone Metastasis – Drug Profile
- GB-223 – Drug Profile
- ITM-41 – Drug Profile
- JMT-103 – Drug Profile
- LG-1980 – Drug Profile
- LX-001 – Drug Profile
- LY-01011 – Drug Profile
- Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis – Drug Profile
- Monoclonal Antibody to Inhibit JAG1 for Bone Metastasis – Drug Profile
- MW-032 – Drug Profile
- OB-002 – Drug Profile
- Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer – Drug Profile
- Rhenium 188Re etidronate – Drug Profile
- RSF-103 – Drug Profile
- Small Molecule to Antagonize PTH for Oncology and Osteoporosis – Drug Profile
- Small Molecules to Inhibit DOCK5 for Bone Metastasis, Post Menopausal Osteoporosis and Rheumatoid Arthritis – Drug Profile
- SON-3015 – Drug Profile
- Tin-117m-DTPA – Drug Profile
- TPH-9 – Drug Profile
- ZL-170 – Drug Profile
- Bone Metastasis – Dormant Projects
- Bone Metastasis – Discontinued Products
- Bone Metastasis – Product Development Milestones
- Featured News & Press Releases
- Aug 31, 2021: Qilu Pharmaceutical Co Ltd received the notice of acceptance
- Dec 15, 2020: Luye Pharma Group : Voluntary announcement denosumab injection (LY01011) commenced phase III clincal trial in China
- Oct 28, 2020: CSPC Pharmaceutical Group : Voluntary announcement first patient dosed in the phase 1 clinical trial of investigational new drug “ALMB-0168”
- Sep 15, 2020: CSPC Pharmaceutical Group: Voluntary Announcement Investigational New Drug “ALMB-0168” obtains clinical trial approval in China
- Nov 27, 2019: CSPC Pharmaceutical: Submission Of clinical trial application for investigational first-in-class new drug ALMB-0168 in Australia
- Jan 05, 2018: NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Bone Metastasis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Universities/Institutes, 2022
- Table 8: Number of Products by Stage and Target, 2022
- Table 9: Number of Products by Stage and Mechanism of Action, 2022
- Table 10: Number of Products by Stage and Route of Administration, 2022
- Table 11: Number of Products by Stage and Molecule Type, 2022
- Table 12: Bone Metastasis – Pipeline by Ablynx NV, 2022
- Table 13: Bone Metastasis – Pipeline by Airsea (Taizhou) Pharmaceutical Ltd, 2022
- Table 14: Bone Metastasis – Pipeline by AlaMab Therapeutics Inc, 2022
- Table 15: Bone Metastasis – Pipeline by Aptacure Therapeutics Ltd, 2022
- Table 16: Bone Metastasis – Pipeline by Better Life Pharmaceuticals Inc, 2022
- Table 17: Bone Metastasis – Pipeline by Biocon Ltd, 2022
- Table 18: Bone Metastasis – Pipeline by BiologicsMD Inc, 2022
- Table 19: Bone Metastasis – Pipeline by BioNTech SE, 2022
- Table 20: Bone Metastasis – Pipeline by Crescendo Biologics Ltd, 2022
- Table 21: Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 22: Bone Metastasis – Pipeline by Eden Biologics Inc, 2022
- Table 23: Bone Metastasis – Pipeline by Genor BioPharma Co Ltd, 2022
- Table 24: Bone Metastasis – Pipeline by Hetero Labs Ltd, 2022
- Table 25: Bone Metastasis – Pipeline by Hualan Biological Engineering Inc, 2022
- Table 26: Bone Metastasis – Pipeline by ITM Isotope Technologies Munich SE, 2022
- Table 27: Bone Metastasis – Pipeline by Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd, 2022
- Table 28: Bone Metastasis – Pipeline by Jiangsu T-mab BioPharma Co Ltd, 2022
- Table 29: Bone Metastasis – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Table 30: Bone Metastasis – Pipeline by Lupin Ltd, 2022
- Table 31: Bone Metastasis – Pipeline by Luye Pharma Group Ltd, 2022
- Table 32: Bone Metastasis – Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022
- Table 33: Bone Metastasis – Pipeline by MetCure Therapeutics LLC, 2022
- Table 34: Bone Metastasis – Pipeline by NeuClone Pty Ltd, 2022
- Table 35: Bone Metastasis – Pipeline by Orion Biotechnology Canada Ltd, 2022
- Table 36: Bone Metastasis – Pipeline by PEKKIP Oncology Alliance AG, 2022
- Table 37: Bone Metastasis – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 38: Bone Metastasis – Pipeline by QSAM Therapeutics Inc, 2022
- Table 39: Bone Metastasis – Pipeline by Sandoz International GmbH, 2022
- Table 40: Bone Metastasis – Pipeline by Serene LLC, 2022
- Table 41: Bone Metastasis – Pipeline by Shanghai Henlius Biotech Inc, 2022
- Table 42: Bone Metastasis – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2022
- Table 43: Bone Metastasis – Dormant Projects, 2022
- Table 44: Bone Metastasis – Dormant Projects, 2022 (Contd..1)
- Table 45: Bone Metastasis – Dormant Projects, 2022 (Contd..2)
- Table 46: Bone Metastasis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Bone Metastasis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.